Innovation starts from the heart. Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease. With millions of patients served in over 100 countries, each team makes a meaningful contribution by improving patient outcomes
Play a critical role in Transcatheter Mitral & Tricuspid Therapies (TMTT) clinical study execution including leading the internal specialist training program and maintain an audit ready environment by ensuring compliance with all physician and training procedures,
Patients with mitral and tricuspid heart valve disease often have complex conditions with limited treatment options. Our Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is boldly pursuing an innovative portfolio of technologies to address a